-
Part 4 | Session 2 Lipid Management & the CLEAR Trial with Dr Erin Michos
-
Part 4 | Session 3 Obesity Management Strategies in 2023 with Dr Harold Bays
-
Part 4 | Session 4 ACC.23 President Interview with Dr B Hadley Wilson
-
Part 5 | Session 1 Dr Akowuah: Cardiovascular Research & Message for Early-Career Researchers
-
Part 5 | Session 2 Dr Kini: Asking Questions & Her Motivation to Do Research on Plaque
-
Part 5 | Session 4 Dr Verma: Passion for Electrophysiology & His Advice For Young Researchers
-
Part 5 | Session 6 Dr Hahn: Innovative Areas of Cardiovascular Science in 2023
-
Part 5 | Session 7 Dr Forrest: Structural Heart Innovations and Advice to Young Researchers
-
Part 1 | Session 1 The CLEAR-Outcomes Trial with Dr Harriette Van Spall & Dr Steven Nissen
-
Part 1 | Session 5 The BIOVASC Trial with Dr Harriette Van Spall & Prof Roberto Diletti
-
Part 2 | Session 1 Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial
-
Part 2 | Session 2 RENOVATE-COMPLEX-PCI: IVUS Vs OCT Optimisation in Complex PCI
-
Part 2 | Session 3 Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study
-
Part 2 | Session 7 MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients
-
Part 2 | Session 8 Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF
-
Part 2 | Session 9 BMAD Trial: μCor in Ambulatory Decompensated Heart Failure
-
Part 3 | Session 1 ACC.23 Late-breaking Science Wrap Up
-
Part 3 | Session 2 What's Hot at ACC.23? Late-breaking Science Preview
Dr Khaled Al-Shaibi and Dr Mirvat Alasnag (The King Fahd Armed Forces Hospital, Jeddah, SB) joined us to discuss the top 5 late-breaking interventional cardiology highlights of ACC.
In this discussion, interventional experts delve into the latest research, findings and considerations for practice from trials, including:
0:29: The RENOVATE-COMPLEX-PCI Trial
6:22: The BIOVASC Trial
7:11: TRILUMINATE Trial
10:30: The COAPT Trial
13:17: The Evolut Low Risk Trial
Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data.
For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
More from this programme
Part 1
Late-Breaker Discussion Series
Part 2
Expert Interviews
Part 3
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023.
Part 4
Highlights Reviews
Faculty Biographies

Mirvat Alasnag
Director of Catheterization Laboratory
Dr Mirvat Alasnag is an editorial board member of Interventional Cardiology: Reviews, Research, Resources (ICR3), joining the board in October 2020 and is also on the editorial board for US Cardiology Review (USC).
Dr Mirvat Alasnag is the Director of the Catheterization Laboratory at the King Fahad Armed Forces Hospital in Jeddah, Saudi Arabia. She was the first female interventional cardiologist in the Gulf region and has since represented women on multiple medical committees, including the Saudi Arabian Cardiac Interventional Society Board & the EAPCI Women’s Steering Committee. She is the current ACCWIC International Working Group Chair and an SCAI WIN member.
Dr Alasnag trained in Clinical Cardiology and Interventional Cardiology at Loma Linda University Medical Center (Loma Linda, California) and Harper University Hospital, Detroit Medical Center (Detroit, Michigan), respectively. Since her graduation in 2009 to date, she has been…

Khaled Al-Shaibi
Director Cardiac Center
Dr Khaled Al-Shaibi is the Director at King Fahd Armed Forces Hospital. He earned his Doctor of Medicine degree from King Abdulaziz University in Jeddah, Saudi Arabia, in 1986.
Dr Al-Shaibi completed his residency in Internal Medicine at the University of Alabama at Birmingham (UAB) Medical Center from 1988 to 1991. Furthering his specialisation, Dr Al-Shaibi completed a Cardiology Fellowship at UAB Medical Center from 1991 to 1994, leading to his ABIM certification in Cardiovascular Disease in 1995. He then pursued advanced training through an Interventional Cardiology Fellowship at UAB Medical Center from 1994 to 1996, earning ABIM certification in Interventional Cardiology in 1997.
Dr Al-Shaibi's outstanding contributions to interventional cardiology in Saudi Arabia have been widely recognised. In 2016, he received the Lifetime Achievement Award from the Saudi Arabian Coronary Interventional Society. His dedication to the field of cardiology was further honoured by…
Comments